BAY.TI - BAYER

TLO - TLO Delayed Price. Currency in EUR
67.03
+0.96 (+1.45%)
At close: 5:14PM CEST
Stock chart is not supported by your current browser
Previous Close66.07
Open66.33
Bid66.99 x 40000
Ask0.00 x 40000
Day's Range66.22 - 67.07
52 Week Range66.22 - 67.07
Volume1,290
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    What Happened in the Stock Market Today

    Home Depot rose despite reporting mixed results, and Elanco announced a deal with Bayer for its animal health business.

  • Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger
    Investor's Business Daily

    Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger

    Elanco Animal Health stock toppled Tuesday after announcing its $7.6 billion takeover of Bayer's animal health segment. Elanco stock plunged almost 9% at the close of the stock market.

  • Barrons.com

    Elanco Stock Tumbles After It Announces a Deal to Acquire Bayer’s Animal-Health Business

    Elanco Animal Health is one of the largest companies in its field and it plans to get a lot bigger with the $7.6 billion acquisition of Bayer’s animal-health business.

  • Benzinga

    Elanco To Acquire Bayer's Animal Health Business For $7.6B

    Elanco Animal Health Inc (NYSE: ELAN ) shares were trading lower Tuesday after the company announced it would acquire Bayer AG (OTC: BAYRY )'s animal health business for $5.32 billion in cash and $2.28 ...

  • Bloomberg

    Elanco to Buy Bayer’s Animal-Health Unit for $7.6 Billion

    (Bloomberg) -- Elanco Animal Health Inc. clinched the purchase of Bayer AG’s animal-health unit in a deal valued at $7.6 billion, creating one of the biggest stand-alone veterinary-medicine companies in the world.Elanco, which was spun out from drugmaker Eli Lilly & Co. last year, will finance the acquisition with a mix of cash and stock. German drug giant Bayer AG will receive $5.32 billion in cash and $2.3 billion in Elanco Animal Health common shares. The transaction is expected to close in mid-2020.“This will create the No. 2 animal-health company,” Elanco Chief Executive Officer Jeffrey Simmons said in an interview. “We see this as a nice complement. The pet owner, the veterinarian and the farmer win in this transaction.”Shares of Elanco have been under pressure since news of the potential transaction first surfaced earlier this summer. Bloomberg reported that the companies were close to a deal on Aug. 7.Elanco declined as much as 6.3% in New York trading on Tuesday. Bayer shares traded in Germany were down less than 0.1%.Elanco, based in Greenfield, Indiana, expects the deal to add to its adjusted earnings per share in the first full year after it closes. Buying the Bayer division will significantly bulk up its pet business at a time when the agricultural sector has turned more volatile. Last week, Elanco narrowed its sales guidance as a result of the outbreak of a deadly swine flu in Asia, which caused a decline in its farm unit.“With a larger, more diverse animal-health company, the percentage of the vulnerability will be less,” Simmons said, adding that he expects the current swine flu outbreak will eventually pass.Pfizer Inc.’s decision to spin out its animal-health business, Zoetis Inc., in 2013 has prodded other drugmakers to shed their veterinary units. The businesses are often stable, profitable operations whose fortunes are more tied to macroeconomic trends like rising global wealth and protein consumption, instead of risky bets on drug research.For Bayer, the sale adds to the resources it could draw from to pay potential costs for thousands of claims that Roundup, the weedkiller it gained in last year’s Monsanto acquisition, causes cancer. Bayer is in discussions on a possible settlement, but reaching a resolution could take months, people familiar with the matter have said.Simmons said Elanco won’t face any exposure to the Roundup suits.Bullish SectorZoetis, the former Pfizer unit, has seen its stock almost triple since it became an independent company. Elanco finished trading on Monday up 24% since its 2018 stock-market debut. Merck & Co. remains the only major pharmaceutical company that has held onto its animal-health unit, which generates about a 10th of its revenue.The deal would make Elanco the second-largest global animal-health business after Zoetis in terms of revenue, increasing its reach among farmers and pet owners. While it would be the new company’s biggest deal as an independent business, parent Eli Lilly bought Novartis AG’s animal-health unit in 2015 for $5.4 billion and combined the two firms’ assets.“Our top focus is now delivering our pipeline, bolt-ons, and other M&A is not needed,” Simmons said.Wall Street analysts have expressed reservations about the potential deal, saying that the Bayer business is unlikely to deliver a significant boost to Elanco’s growth.“Elanco is buying what I view as a flat-to-declining business that doesn’t innovate and has a high concentration risk,” Kevin Ellich, an analyst at Craig-Hallum Capital Group, said in an interview before the deal was announced. “The deal is dilutive to shareholders. At the end of the day, it’s just not that attractive. I don’t see how the stock goes up.”Simmons said he’s looking forward to setting the record straight with investors. “Now we’re able to respond to the marketplace: There’s been no change in our strategy, this is about growth and innovation,” he said.Elanco intends to work with regulators on potential antitrust issues, but sees the two portfolios as complementary.Goldman Sachs served as financial adviser to Elanco, while Paul, Weiss, Rifkind, Wharton & Garrison LLP and Hengeler Mueller were its legal counsel. Elanco’s board of directors was provided a fairness opinion by Duff & Phelps. Bank of America Merrill Lynch and Credit Suisse acted as financial advisers to Bayer, while Sullivan & Cromwell, PwC Legal and Linklaters served as its legal advisers.(Updates stock-price information in fifth paragraph)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Financial Times

    Bayer agrees $7.6bn sale of animal health business to Elanco

    Bayer has agreed to sell its animal health unit to sector specialist Elanco for $7.6bn, as the German pharmaceuticals and chemicals group sells off assets in the face of mounting legal claims linked to its disastrous $63bn acquisition of Monsanto. Bayer is to be paid $5.32bn, or 70 per cent of the total, in cash, with the remaining $2.28bn made up of Elanco shares.

  • UPDATE 3-Elanco to become No.2 in animal health with $7.6 bln Bayer deal
    Reuters

    UPDATE 3-Elanco to become No.2 in animal health with $7.6 bln Bayer deal

    Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online. The deal is the latest in the fast-growing animal health market, which has recently seen Elanco floated by Eli Lilly and Co and rival U.S. drugmaker Pfizer also spinning off its veterinary medicine business.

  • Elanco to buy Bayer's animal health unit for $7.6 billion
    Reuters

    Elanco to buy Bayer's animal health unit for $7.6 billion

    Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space. The animal health market has seen Pfizer Inc and Eli Lilly and Co, successfully floating their veterinary medicine units on the stock market as independent entities.

  • TheStreet.com

    [video]Elanco to Buy Bayer's Animal Health Business for $7.6 Billion

    Elanco says the deal, which is subject to approval from regulators, would double the size of its companion animal business.

  • Elanco Narrows Guidance Amid Spread of African Swine Fever
    Bloomberg

    Elanco Narrows Guidance Amid Spread of African Swine Fever

    (Bloomberg) -- Elanco Animal Health Inc. narrowed its sales forecast for the year as a worsening outbreak of a deadly swine flu ravages the pork industry in Asia.The company, which was spun off last year from drugmaker Eli Lilly & Co., reined in the higher end of its revenue outlook, saying it now sees 2019 sales of $3.08 billion to $3.12 billion, compared with the $3.08 billion to $3.14 billion it had forecast in May.African swine fever has led to the slaughter of millions of animals in China as officials seek to contain the outbreak and limit the damage to the country’s pork producers. The virulent flu jumped from Africa to Europe and spread quickly in Asia. For companies like Elanco, the culling of livestock has led to lower demand for medicines and other products.“I haven’t seen something like this in my 30 years working in animal health,” said Elanco Chief Executive Officer Jeff Simmons in a telephone interview. He said that swine fever is the most significant headwind the company faces. The disease is expected to cut into Elanco’s sales by $40 million to $50 million this year, the company said.Elanco is meanwhile weighing steps to get bigger. Last week, Bloomberg reported that Elanco is attempting to reach a deal to combine with Bayer AG’s animal-health unit.Chief Financial Officer Todd Young said on a conference call that Elanco is postponing the initiation of a dividend so the company can use its cash “in the most productive way possible.”Shares of Elanco gained as much as 2.9% to $30.40 in New York on Tuesday.Street SkepticismWall Street has been skeptical about Elanco’s bid for the Bayer division. Since July 8, the day before Reuters reported that the companies were in talks, Elanco’s shares are down about 9%.While Bayer prefers a deal with Elanco, no final agreements have been reached and the talks could drag on or fall apart, people familiar with the matter told Bloomberg. Bayer may proceed with its previous plans for a broader auction process if it can’t agree on terms with Elanco by early September, one of the people said at the time.Asked repeatedly about the possible combination with Bayer on the call with investors, Simmons said Elanco is always “evaluating vectors of risk and opportunity.” He declined to comment further on the potential deal.“We believe we have the scale and the global reach that we need,” Simmons said in the telephone interview. “We’ll continue to expand and accelerate this strategy, we’ll continue to bolt-on.”Elanco’s pet businesses helped offset the sales declines in the farm unit in the most recent quarter, with disease prevention sales increasing 4% from a year earlier to $223.4 million and therapeutics sales rising 22% to $83.4 million.Second-quarter adjusted earnings were 28 cents a share, the company said in a statement, topping an average of analysts’ estimates.(Updates with comments from conference call in sixth paragraph)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Barrons.com

    Elanco Stock Jumps Because There’s No Sign of Bayer Merger Yet

    The company didn’t announce a reported merger with Bayer A.G. that had been expected to be announced Tuesday.

  • Barrons.com

    Bayer Stock Will Soar 30% If It Strikes $8 Billion Roundup Settlement, But It’s a Big If

    German chemical company Bayer’s stock could soar if the company can agree to settle more than 18,000 lawsuits claiming that its Roundup weedkiller causes cancer.

  • Financial Times

    Bayer boosted by report of $8bn settlement proposal in pesticide legal battle

    Shares in Bayer jumped 8 per cent on Friday after a media report suggested that the German chemicals and pharmaceuticals group was in talks to settle its sprawling legal battle in the US over the Roundup pesticide for as much as $8bn. Bayer has been under intense pressure from shareholders to put an end to the avalanche of legal claims alleging that Roundup, a weed killer that contains glyphosate, causes cancer. According to a report by Bloomberg, Bayer’s legal team is currently holding talks in New York City with plaintiff lawyers aimed at settling all outstanding and future claims.

  • Bayer mediator dismisses report of $8 bln Roundup settlement
    Reuters

    Bayer mediator dismisses report of $8 bln Roundup settlement

    NEW YORK/FRANKFURT (Reuters) - Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher. "Bayer has not proposed paying $8 billion to settle all the U.S. Roundup cancer claims. Such a statement is pure fiction," Feinberg said in an email on Friday.

  • Bayer mediator dismisses report of $8 billion Roundup settlement
    Reuters

    Bayer mediator dismisses report of $8 billion Roundup settlement

    NEW YORK/FRANKFURT (Reuters) - Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher. "Bayer has not proposed paying $8 billion to settle all the U.S. Roundup cancer claims. Such a statement is pure fiction," Feinberg said in an email on Friday.

  • TheStreet.com

    Bayer Shares Surge on Report of $8 Billion Roundup Weedkiller Settlement

    Bayer shares traded sharply higher Friday, well outpacing the broader German market, following a report that suggested it could pay $8 billion to settle thousands of lawsuits linked to its Roundup weedkiller.

  • Benzinga

    Bayer To Buy Out Stem Cell Therapy Company BlueRock For Up To $600M

    German chemicals and pharma company Bayer AG (OTC: BAYRY) announced an agreement Thursday to buy out the remaining stake it does not already own in Cambridge, Massachusetts-based BlueRock Therapeutics, a privately held stem cell therapy company. BlueRock was established in 2016 as a joint venture between Bayer and Versant Ventures, with the former holding a 40.8% stake. BlueRock's cell therapy portfolio focuses on neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell, or iPSC platform.

  • Bayer buys BlueRock in $600 million bet on stem cell therapies
    Reuters

    Bayer buys BlueRock in $600 million bet on stem cell therapies

    German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline. Having established BlueRock as part of a 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday. BlueRock, valued at about $1 billion by the deal, is working on induced pluripotent stem cells (iPSC), made by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

  • MarketWatch

    Bayer to acquire biotech BlueRock Therapeutics

    Bayer AG is acquiring BlueRock Therapeutics, a privately-held U.S.-based biotech developing engineered cell therapies in the areas of neurology, cardiology and immunology, the companies announced Thursday. BlueRock was established in 2016 through a joint venture between Bayer and Versant Ventures. Germany-based Bayer currently holds a 40.8% stake and will acquire the rest for around $240 million. Bayer could also pay an additional $360 million if BlueRock meets certain research milestones, valuing BlueRock at around $1 billion. The transaction is expected to close during the third quarter of 2019. "This acquisition marks a major milestone on our path towards a leading position in cell therapy," said Stefan Oelrich, president of Bayer's pharmaceuticals division. Shares of Bayer have fallen 3.1% in the year to date through Wednesday, while the S&P 500 has gained 15%.

  • Financial Times

    Bayer to buy rest of US biotech company in rare offensive move

    Bayer has agreed to take full control of BlueRock Therapeutics, in a deal that values the US biotech company at up to $1bn. The German pharmaceuticals and chemicals group will pay $240m upfront, and will pay an additional $360m upon achievement of “predefined development milestones”. Bayer already owns 41 per cent of BlueRock, which it set up as a joint venture with Versant Ventures in 2016.

  • Elanco, Bayer Are Aiming to Reach Animal-Health Deal Next Week
    Bloomberg

    Elanco, Bayer Are Aiming to Reach Animal-Health Deal Next Week

    (Bloomberg) -- Elanco Animal Health Inc., the business Eli Lilly & Co. listed last year, is aiming to reach an agreement as soon as next week to combine with Bayer AG’s animal-health unit, people with knowledge of the matter said.The companies hope to announce a deal around the time of Elanco’s Aug. 13 earnings release, the people said, asking not to be identified as the discussions are private. Elanco, which has a market value of about $12.3 billion, plans to pay at least part of the acquisition cost using stock, the people said.Elanco lost 4.2% Wednesday to close at $31.47. Bayer rose as much as 2.6% early Thursday in Frankfurt.Bayer is selling units to sharpen its focus after the $63 billion purchase of Monsanto, which saddled it with thousands of lawsuits claiming that the Roundup weedkiller it acquired in that deal causes cancer. The German giant agreed to unload its majority stake in a chemicals venture Wednesday in a deal valued at $3.9 billion, and two Roundup trials have been delayed as pressure builds on Chief Executive Officer Werner Baumann to fashion a settlement.Bayer would get a significant minority stake in Elanco under the deal being discussed, according to another person. The companies are currently hammering out potential antitrust issues by identifying which businesses they will likely need to sell to gain regulatory approval, the person said.While Bayer prefers a deal with Elanco, no final agreements have been reached and the talks could drag on or fall apart, the people said. Bayer may proceed with its previous plans for a broader auction process if it can’t agree on terms with Elanco by early September, one person said.Serial AcquirerA deal between Elanco and Bayer would preempt a sale process that was expected to be one of Europe’s most hotly contested deal situations this year. It had attracted a flurry of initial interest from buyout firms ranging from KKR & Co. to Blackstone Group Inc. and CVC Capital Partners, which have increasingly been bidding against each other as they try to spend the record amounts of capital the industry has amassed.Bayer said in a statement that it’s on track with plans to exit the animal-health business and its primary focus is on a sale. The German company also continues to consider all value-maximizing options, it said in the statement, declining to comment further.Elanco has grown rapidly through at least 10 acquisitions since 2007, including the $5.4 billion takeover of Novartis AG’s animal-health unit. A representative for Elanco, which is based outside Indianapolis, declined to comment.Ambitious BetsThe sale of Bayer’s animal-health unit was expected to fetch as much as 8 billion euros ($9 billion), Bloomberg News has reported. The process was initially slated to kick off in the second quarter, people with knowledge of the matter said in March, though Bayer has repeatedly pushed back the start of the auction.The Bayer business offers medicine and antibiotics to farm animals and pets. The division’s best-selling product line is the Advantage flea, tick and worm treatments for small animals.Drugmakers including Lilly, Bayer and Pfizer Inc. have all offloaded their animal-health units in recent years. The businesses are often stable, profitable operations that go unrecognized inside larger pharmaceutical firms increasingly focused on ambitious research bets.(Updates with shares in third paragraph.)\--With assistance from Tim Loh and Nabila Ahmed.To contact the reporters on this story: Riley Griffin in New York at rgriffin42@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.netTo contact the editors responsible for this story: Liana Baker at lbaker75@bloomberg.net, ;Drew Armstrong at darmstrong17@bloomberg.net, ;Fion Li at fli59@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Financial Times

    Bayer’s Monsanto acquisition leaves it with a toxic legacy

    FT premium subscribers can click here to receive Due Diligence every day by email. In that spirit, we’ve launched a Fantasy Premier League for our readers to compete against DD writers and FT reporters.